64x Bio develops a high throughput genome engineering platform that accelerates the discovery of optimized mammalian cell lines for cell and gene therapies. This technology enables pharmaceutical and biotechnology companies to efficiently design and manufacture next-generation therapeutics, addressing the challenges of traditional cell line development.

Basil Systems provides a cloud‑based SaaS platform that consolidates global pharmaceutical and MedTech data—regulatory filings, adverse event reports, market intelligence, and clinical information—into a unified, searchable repository. Using AI and advanced analytics, the platform delivers real‑time insights such as label comparisons, precedent identification, safety signal detection, and predictive patterns, while automating routine tasks like CER/PSUR table generation to accelerate decision‑making and time‑to‑market.

Chemify is a platform that digitizes chemistry and chemical discovery by executing chemical code for drug discovery, synthesis, and materials development. This technology accelerates the synthesis of complex molecules and enables the creation of extensive functional libraries, enhancing reproducibility and efficiency in molecular optimization.

Circularise provides a product traceability platform designed to manage supply chain compliance and data integrity across complex value chains. The platform automates supplier data collection and internal bookkeeping to support frameworks like ISCC PLUS and REDcert-EU. This enables businesses to generate verifiable Digital Product Passports (DPPs) for regulatory readiness and enhanced sustainability reporting.

Clora is an intelligent platform that utilizes advanced algorithms to match life science companies with highly experienced consultants for project-specific needs. This approach addresses the inefficiencies of traditional recruitment by providing faster placements, reduced costs, and access to a global talent pool, ensuring that companies can quickly find the right expertise for their fluctuating project demands.

Cytosolix develops oral and intravenous formulations that specifically target tumor acidity to enhance the effectiveness of small molecule cancer therapies. By addressing the acidic microenvironment of tumors, these derivatives aim to improve therapeutic outcomes for cancer patients.

Elegen utilizes proprietary cell-free DNA synthesis technology to produce long, complex, linear DNA up to 7 kb with 99.999% accuracy, eliminating the need for cloning. This rapid synthesis, delivered in 6 to 8 business days, addresses the critical bottleneck in DNA supply for synthetic biology applications, significantly reducing project timelines and costs.

Endpoint provides an AI-powered platform for generating Real-World Evidence (RWE) studies quickly. The platform leverages a network of over 25 million multimodal, longitudinal patient records to deliver instant insights across various therapeutic areas. This capability supports researchers and pharmaceutical companies in areas like comparative effectiveness, label expansion, and trial design.

Galatea Bio designs and executes projects leveraging human genetic diversity for biomedical problem-solving. The company offers clinical testing services through a CLIA-CMS certified molecular diagnostics laboratory and biobank infrastructure. They partner with life sciences organizations to build large-scale population sequencing programs utilizing an extensive genomic-phenotypic data lake.

Ko is a networking platform that organizes educational resources and facilitates the creation of professional profiles for individuals and teams. It addresses the challenge of connecting job seekers with educational opportunities by providing a centralized space for resource sharing and job postings.

Mythic provides analog compute‑in‑memory AI inference accelerators that integrate compute and weight storage on a single silicon plane, eliminating off‑chip memory traffic. Delivered as standard M.2 cards, the APUs achieve up to 25 TOPS with 3‑4× lower power than comparable digital accelerators, and are compatible with TensorFlow and PyTorch for edge devices such as robots, drones, and smart‑city cameras.

Pair Team is an operations platform that connects vulnerable patients with local care teams through coordinated care management and resource allocation. By partnering with community organizations, it addresses gaps in healthcare access and improves patient engagement, resulting in a 34% reduction in emergency room visits and a 21% increase in re-engagement with primary care providers.

This startup provides homeowners insurance services that utilize artificial intelligence and physics to assess wildfire risks and recommend property fortification strategies. By enabling property owners to enhance their resilience against wildfires while maintaining their property's unique characteristics, the company addresses the increasing threat of wildfire damage to homes.

This company provides an AI-driven platform to accelerate independent musician careers through digital distribution and financial resources. It offers streaming royalty advances ranging from $1,000 to $1 million for release investment. The platform also delivers career assessments based on over 275 criteria and intelligent recommendations derived from global music data.

The startup operates a web portal that facilitates direct, commission-free connections between artists, companies, producers, and programmers through a searchable directory featuring presentation sheets, contact information, and multimedia content. This platform addresses the challenge of fragmented communication in the creative industry by enabling streamlined access to programming talent and resources.

Xilis provides an end‑to‑end platform that generates patient‑derived 3D micro‑organoids (MOS®) preserving tissue heterogeneity for drug testing. The system automates high‑throughput model production, supports modular phenotypic and immune assays, and applies AI‑driven analytics to deliver quantitative efficacy and safety predictions via a secure cloud dashboard. It serves pharmaceutical, biotechnology, CRO and academic customers needing scalable, high‑fidelity preclinical models.

Zafrens utilizes nanofabrication to analyze and manipulate diverse cell populations at single-cell resolution, generating paired longitudinal imaging and sequencing data. This technology enables high-throughput drug discovery across various modalities, enhancing our understanding of cellular behavior and facilitating scientific discoveries at an unprecedented scale.